12:00 AM
 | 
Dec 21, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Taspoglutide: Phase III data

The double-blind, international Phase III T-emerge 7 trial in 305 obese patients with Type II diabetes showed that subcutaneous weekly taspoglutide as an add-on to metformin met the primary endpoint of superiority to placebo in reducing HbA1c at 24 weeks. Taspoglutide was well tolerated, with nausea and vomiting the most frequent adverse...

Read the full 240 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >